News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GI Dynamics Announces First Clinical Study to Demonstrate Improvement in Weight Loss and Co-morbid Conditions Following EndoBarrier™ Re-implantation



10/22/2012 9:47:33 AM

EXINGTON, Mass. & AMSTERDAM--(BUSINESS WIRE)--GI Dynamics, Inc. (ASX: GID) today announced the first study evaluating the long-term benefits and safety of re-implanting EndoBarrier® to extend weight loss benefits for three years. Data suggest EndoBarrier may be re-implanted approximately one year after completion of the initial treatment period, which may help obese people experience additional weight loss, long-term weight loss maintenance and improvement in other co-morbid conditions, including cholesterol, blood pressure and fasting blood glucose (FPG), a key measure of blood sugar levels used to diagnose diabetes.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES